This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (79)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Ophthalmol. 2001;119:1380-1383.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Birdshot retinochoroidopathy is a chronic, bilateral uveitic disorder. Originally described by Ryan and Maumenee,¹ it is characterized by posterior segment inflammation in the presence of multiple depigmented choroidal lesions symmetrically scattered throughout the postequatorial retina. The cause is presumed to be autoimmune and more than 90% of patients test positive for the HLA-A29 serotype.² Approximately half of affected eyes develop cystoid macular edema (CME), and this represents a major cause of considerable visual loss from this condition.³ A rationale for treatment with corticosteroids has been established based on the inflammatory nature of the disease. However, systemic and periocular corticosteroids have failed to produce significant improvement in most treated patients.⁴ We report 2 cases of refractory CME secondary to birdshot retinochoroidopathy that were successfully treated with intravitreal injections of triamcinolone acetonide.

Report of Cases

Case 1

A 60-year-old woman was diagnosed with birdshot retinochoroidopathy 3 years prior to initial examination. She was positive for HLA-A29 and . . . [Full Text of this Article]

Case 2

Comment
Corresponding author: Jay S. Duker, MD, 750 Washington St, Box 450, Boston, MA 02111.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Preparation and Characterization of Triamcinolone Acetonide-loaded Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHx) Microspheres
Bayram et al.
Journal of Bioactive and Compatible Polymers 2008;23:334-347.
ABSTRACT  

The Role of Topical Antibiotic Prophylaxis for Intravitreal Injections
Scott and Flynn
Arch Ophthalmol 2007;125:974-976.
FULL TEXT  

Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations
Gutfleisch et al.
Br. J. Ophthalmol. 2007;91:345-348.
ABSTRACT | FULL TEXT  

Intravitreal anti-inflammatory treatment for uveitis
Sugita
Br. J. Ophthalmol. 2007;91:135-136.
FULL TEXT  

Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye
Kosobucki et al.
Br. J. Ophthalmol. 2006;90:705-708.
ABSTRACT | FULL TEXT  

Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy.
Bandello et al.
Arch Ophthalmol 2006;124:643-650.
ABSTRACT | FULL TEXT  

Should corticosteroids be considered as part of the standard care with photodynamic therapy?
Zarbin
Arch Ophthalmol 2006;124:563-571.
FULL TEXT  

Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema
Jonas et al.
Arch Ophthalmol 2005;123:1338-1343.
ABSTRACT | FULL TEXT  

Acute Endophthalmitis Incidence: Intravitreal Triamcinolone
Westfall et al.
Arch Ophthalmol 2005;123:1075-1077.
ABSTRACT | FULL TEXT  

Effect of Intravitreal Triamcinolone Acetonide on Susceptibility to Experimental Bacterial Endophthalmitis and Subsequent Response to Treatment
Bucher et al.
Arch Ophthalmol 2005;123:649-653.
ABSTRACT | FULL TEXT  

Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study
Jonas et al.
Br. J. Ophthalmol. 2005;89:321-326.
ABSTRACT | FULL TEXT  

Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration
Jonas et al.
Br. J. Ophthalmol. 2004;88:1557-1562.
ABSTRACT | FULL TEXT  

Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study
Ciardella et al.
Br. J. Ophthalmol. 2004;88:1131-1136.
ABSTRACT | FULL TEXT  

Safety of an Intravitreal Injection of Triamcinolone: Results From a Randomized Clinical Trial
Gillies et al.
Arch Ophthalmol 2004;122:336-340.
ABSTRACT | FULL TEXT  

Intravitreal Reinjection of Triamcinolone for Exudative Age-Related Macular Degeneration
Jonas et al.
Arch Ophthalmol 2004;122:218-222.
ABSTRACT | FULL TEXT  

Noninfectious Endophthalmitis Associated With Intravitreal Triamcinolone Injection
Roth et al.
Arch Ophthalmol 2003;121:1279-1282.
ABSTRACT | FULL TEXT  

Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis
Okada et al.
Br. J. Ophthalmol. 2003;87:968-971.
ABSTRACT | FULL TEXT  

Pseudo-endophthalmitis after intravitreal injection of triamcinolone
Sutter and Gillies
Br. J. Ophthalmol. 2003;87:972-974.
ABSTRACT | FULL TEXT  

Intravitreal triamcinolone acetonide for exudative age related macular degeneration
Jonas et al.
Br. J. Ophthalmol. 2003;87:462-468.
ABSTRACT | FULL TEXT  

Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis
Degenring and Jonas
Br. J. Ophthalmol. 2003;87:361-361.
FULL TEXT  

Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema
Jonas et al.
Arch Ophthalmol 2003;121:57-61.
ABSTRACT | FULL TEXT  

Modulation of Permeability and Adhesion Molecule Expression by Human Choroidal Endothelial Cells
Penfold et al.
IOVS 2002;43:3125-3130.
ABSTRACT | FULL TEXT  

Intravitreal triamcinolone in recurrence of choroidal neovascularisation
Penfold
Br. J. Ophthalmol. 2002;86:600-601.
FULL TEXT